ALLK:NSD-Allakos Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 108.09

Change

+0.09 (+0.08)%

Market Cap

USD 5.73B

Volume

0.11M

Avg Analyst Target

USD 159.00 (+47.10%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Allakos Inc. operates as a clinical stage biopharmaceutical company. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; and a Phase II/III study for the treatment of eosinophilic esophagitis. The is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, severe allergic conjunctivitis, chronic urticaria, and indolent systemic mastocytosis. Allakos Inc. was incorporated in 2012 and is headquartered in Redwood City, California. Address: 975 Island Drive, Redwood City, CA, United States, 94065

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-09-22 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

+6.68 (+1.54%)

USD175.20B 51.28 41.56
BNTX BioNTech SE

-2.09 (-0.61%)

USD82.22B 18.72 15.10
REGN Regeneron Pharmaceuticals Inc

+0.11 (+0.02%)

USD69.19B 11.68 8.91
VRTX Vertex Pharmaceuticals Incorpo..

-1.53 (-0.82%)

USD48.20B 24.50 16.63
BGNE BeiGene Ltd

-0.33 (-0.08%)

USD41.72B N/A N/A
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
SGEN Seagen Inc

+4.15 (+2.51%)

USD30.02B 51.49 39.11
GMAB Genmab A/S

-0.22 (-0.50%)

USD28.07B 71.33 8.17
RPRX Royalty Pharma plc

-0.34 (-0.93%)

USD22.24B 29.66 12.50
ALNY Alnylam Pharmaceuticals Inc

-1.94 (-1.05%)

USD21.89B N/A N/A

ETFs Containing ALLK

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -22.79% 39% F 19% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -22.79% 39% F 19% F
Trailing 12 Months  
Capital Gain 37.68% 68% D+ 53% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 37.68% 68% D+ 51% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 38.17% 68% D+ 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 38.17% 68% D+ 79% C+
Risk Return Profile  
Volatility (Standard Deviation) 44.25% 70% C- 41% F
Risk Adjusted Return 86.27% 97% A+ 89% B+
Market Capitalization 5.73B 93% A 87% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 10.32 16% F 14% F
Price / Cash Flow Ratio -50.25 90% A- 87% B+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -39.12% 69% D+ 33% F
Return on Invested Capital -27.31% 73% C 25% F
Return on Assets -22.09% 57% F 17% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 17.11 6% F 3% F
Short Percent 8.87% 29% F 20% F
Beta 0.89 72% C- 67% D+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.